Fanapt

Increased mortality in elderly patients with dementia-related psychosis (not approved use). Bradycardia, hypokalemia, hypomagnesemia, congenital QT prolongation, recent MI, uncompensated heart failure, arrhythmias: avoid (risk of torsades de pointes/ sudden death). Discontinue if persistent QTc measurements >500msec occur. Cardio- or cerebrovascular disease. Monitor electrolytes esp. K⁺, Mg⁺⁺. Monitor for neuroleptic malignant syndrome (NMS); discontinue if suspected and treat appropriately. Consider discontinuing if tardive dyskinesia occurs; assess periodically the need for continued treatment. Moderate hepatic impairment. Severe hepatic impairment: not recommended. Diabetes or risk factors (obtain baseline fasting blood sugar). Dyslipidemia (obtain baseline fasting lipid profile). Monitor for blood glucose, lipid profile, weight changes. History of breast cancer or seizures. Orthostatic hypotension. Preexisting low WBC count or history of leukopenia/neutropenia: monitor CBC during 1^st few months of therapy; discontinue if WBCs decline. If neutropenia develops, monitor for fever, signs/symptoms of infection; discontinue if severe neutropenia (absolute neutrophil count <1000/mm³) occurs. Exposure to extreme heat. Aspiration pneumonia risk. Dehydration. Perform fall risk assessments when initiating and recurrently on long-term therapy. Risk of intraoperative floppy iris syndrome (IFIS) during cataract or glaucoma surgery: not recommended. Write ℞ for the smallest practical amount. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3^rd-trimester pregnancy). Reevaluate periodically. Pregnancy. Nursing mothers: not recommended.

Increased mortality in elderly patients with dementia-related psychosis (not approved use). Bradycardia, hypokalemia, hypomagnesemia, congenital QT prolongation, recent MI, uncompensated heart failure, arrhythmias: avoid (risk of torsades de pointes/ sudden death). Discontinue if persistent QTc measurements >500msec occur. Cardio- or cerebrovascular disease. Monitor electrolytes esp. K⁺, Mg⁺⁺. Monitor for neuroleptic malignant syndrome (NMS); discontinue if suspected and treat appropriately. Consider discontinuing if tardive dyskinesia occurs; assess periodically the need for continued treatment. Moderate hepatic impairment. Severe hepatic impairment: not recommended. Diabetes or risk factors (obtain baseline fasting blood sugar). Dyslipidemia (obtain baseline fasting lipid profile). Monitor for blood glucose, lipid profile, weight changes. History of breast cancer or seizures. Orthostatic hypotension. Preexisting low WBC count or history of leukopenia/neutropenia: monitor CBC during 1^st few months of therapy; discontinue if WBCs decline. If neutropenia develops, monitor for fever, signs/symptoms of infection; discontinue if severe neutropenia (absolute neutrophil count <1000/mm³) occurs. Exposure to extreme heat. Aspiration pneumonia risk. Dehydration. Perform fall risk assessments when initiating and recurrently on long-term therapy. Risk of intraoperative floppy iris syndrome (IFIS) during cataract or glaucoma surgery: not recommended. Write ℞ for the smallest practical amount. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3^rd-trimester pregnancy). Reevaluate periodically. Pregnancy. Nursing mothers: not recommended.